Fen-Phen Valve Disease: A Real Entity?
- 1 November 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Pathology Case Reviews
- Vol. 6 (6) , 281-286
- https://doi.org/10.1097/00132583-200111000-00007
Abstract
The issue of anorexigen-associated valvular dysfunction and the formation of distinctive lesions predominantly on left-sided heart valves remains an area of intense scientific study and debate. Much controversy remains regarding the specific pathologic and histopathologic features of the myxomatous lesions associated with exposure to anorexigenic agents such as fenfluramine, dexfenfluramine and phentermine. The pathology of heart valve lesions associated with anorexigen exposure must be differentiated from lesions associated with ergotamine and methysergide use and from chronic rheumatic valve disease, floppy valve disease, infective endocarditis and carcinoid heart disease. Heightened awareness of heart valve disease associated with anorexigen exposure as a real pathobiological entity, together with increasing knowledge of the mechanisms involved, should lead to more effective diagnosis and treatment of affected individuals.Keywords
This publication has 35 references indexed in Scilit:
- Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart diseaseThe American Journal of Cardiology, 2000
- Diet Drug-Related Cardiac Valve Disease: The Mayo Clinic Echocardiographic Laboratory ExperienceMayo Clinic Proceedings, 2000
- Valvular Abnormalities and Cardiovascular Status Following Exposure to Dexfenfluramine or Phentermine/FenfluramineJAMA, 2000
- Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramineThe American Journal of Cardiology, 1999
- Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 monthsJournal of the American College of Cardiology, 1999
- Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North DakotaThe American Journal of Cardiology, 1999
- Risk for Valvular Heart Disease among Users of Fenfluramine and Dexfenfluramine Who Underwent Echocardiography before Use of MedicationAnnals of Internal Medicine, 1998
- An Assessment of Heart-Valve Abnormalities in Obese Patients Taking Dexfenfluramine, Sustained-Release Dexfenfluramine, or PlaceboNew England Journal of Medicine, 1998
- The Prevalence of Cardiac Valvular Insufficiency Assessed by Transthoracic Echocardiography in Obese Patients Treated with Appetite-Suppressant DrugsNew England Journal of Medicine, 1998
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997